Dynamic Technology Lab Private Ltd Buys Shares of 33,869 Inari Medical, Inc. (NASDAQ:NARI)

Dynamic Technology Lab Private Ltd purchased a new stake in Inari Medical, Inc. (NASDAQ:NARI) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 33,869 shares of the company’s stock, valued at approximately $1,397,000.

Other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. raised its stake in Inari Medical by 11.1% during the first quarter. Vanguard Group Inc. now owns 5,599,854 shares of the company’s stock worth $268,681,000 after acquiring an additional 561,562 shares in the last quarter. Bessemer Group Inc. increased its position in Inari Medical by 16.4% during the 1st quarter. Bessemer Group Inc. now owns 2,439 shares of the company’s stock worth $117,000 after purchasing an additional 344 shares in the last quarter. CANADA LIFE ASSURANCE Co lifted its stake in Inari Medical by 85.5% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 53,287 shares of the company’s stock valued at $2,550,000 after purchasing an additional 24,562 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in Inari Medical by 0.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 373,347 shares of the company’s stock valued at $17,914,000 after buying an additional 2,003 shares in the last quarter. Finally, iA Global Asset Management Inc. grew its stake in shares of Inari Medical by 78.9% during the first quarter. iA Global Asset Management Inc. now owns 96,770 shares of the company’s stock worth $4,643,000 after buying an additional 42,680 shares during the last quarter. Institutional investors and hedge funds own 90.98% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on NARI. Robert W. Baird increased their price target on Inari Medical from $66.00 to $67.00 and gave the company an “outperform” rating in a research note on Tuesday, October 29th. Piper Sandler lifted their price target on Inari Medical from $50.00 to $52.00 and gave the company a “neutral” rating in a research note on Tuesday, October 29th. Leerink Partnrs raised Inari Medical to a “hold” rating in a research note on Tuesday, September 3rd. Leerink Partners assumed coverage on shares of Inari Medical in a research report on Tuesday, September 3rd. They set a “market perform” rating and a $47.00 target price on the stock. Finally, Needham & Company LLC reissued a “hold” rating on shares of Inari Medical in a report on Tuesday, October 29th. Six equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $58.89.

Insider Buying and Selling

In related news, CFO Mitch C. Hill sold 3,000 shares of the company’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $45.13, for a total transaction of $135,390.00. Following the sale, the chief financial officer now owns 179,600 shares in the company, valued at $8,105,348. This represents a 1.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director William Hoffman sold 40,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $45.02, for a total value of $1,800,800.00. Following the sale, the director now directly owns 601,233 shares of the company’s stock, valued at $27,067,509.66. This represents a 6.24 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 186,000 shares of company stock valued at $8,990,990 over the last quarter. Insiders own 10.60% of the company’s stock.

Inari Medical Stock Performance

Inari Medical stock opened at $50.83 on Wednesday. The firm has a 50 day moving average price of $45.73 and a two-hundred day moving average price of $47.38. Inari Medical, Inc. has a 52-week low of $36.73 and a 52-week high of $67.13. The firm has a market cap of $2.98 billion, a price-to-earnings ratio of -37.65 and a beta of 0.96.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.